When the COVID-19 pandemic hit in my late 40s, exercise completely fell by the wayside, and I wasnt eating as well as I thought I had no sense of portion size and ate very little protein
Beyond Novo and Eli Lilly, companies such as Boehringer Ingelhium, Pfizer, Roche, AstraZeneca, Regor therapeutics, Viking Therapeutics, Amgen, BioAge Labs, Gan & Lee Pharmaceuticals, Sun Pharma, Innovent Biologics, Aphaia Pharma, Vertex Pharmaceuticals , and others are entering the space, fueling new innovations in GLP-1 therapies, combination therapies, and next-gen metabolic treatments
The gut-lymph model gives new treatment strategies for organ failure
But, Semaglutide has gained attention for its weight-loss potential
Semaglutide reverses one womans symptoms After moving to Colorado and finally being diagnosed by a nurse practitioner, Hamilton joined a clinical trial in October 2024 at the University of Colorado Anschutz evaluating semaglutide the popular diabetes-turned-weight-loss drug as a therapy for PMOS
Tirzepatide may help brands that are looking for Newer technology with two receptors Differentiation of products New platforms for peptides Semaglutide might be good for businesses that are looking for: GLP-1 technology that is well known Clinical information that is known Pathways for mature growth Which option is best for a business relies on its technical goals, target market, and product plan